Physician profile
Jamil Ahmed
NPI 1871512376
$1,380.43
in general payments reported to CMS, 2019-2025
26 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $137 · 2021: $138 · 2022: $393 · 2023: $123 · 2024: $224 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $460.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $159.30 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Abbott Laboratories | $141.24 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $130.39 | 2019-2022 | |
| Novo Nordisk INC | $96.31 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $92.42 | 2022 | |
| Abbvie INC. | $73.34 | 2021-2023 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $68.93 | 2025 | Rexulti |
| Allergan, INC. | $66.61 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.08 | 2019-2022 | |
| Astellas Pharma US INC | $61.46 | 2019-2022 | |
| Glaxosmithkline, LLC. | $60.86 | 2019-2024 | Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $56.14 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $46.63 | 2022 | |
| Acadia Pharmaceuticals INC | $42.38 | 2019-2021 | |
| Pfizer INC. | $38.39 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $36.12 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.33 | 2022 | |
| Axsome Therapeutics, INC. | $23.40 | 2023 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.54 | 2025 | Xifaxan |
| Daiichi Sankyo INC. | $14.24 | 2023 | Injectafer |
| Exact Sciences Corporation | $13.61 | 2025 | Cologuard Collection Kit |
| Biogen, INC. | $12.31 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.94 | 2019 | |
| Amgen INC. | $11.81 | 2019 | |
| Urovant Sciences INC | $11.65 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamil Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.